Business Wire

Shin-Etsu Chemical has developed new process technologies, transfer parts and other equipment for Micro LED displays

Share

Shin-Etsu Chemical Co., Ltd. (Head Office: Tokyo; President: Yasuhiko Saitoh) has developed new process technologies that can be applied for the manufacturing of Micro LED displays.

The size of a Micro LED chip is not visible to the naked eye, with the length of one side being less than 50 μm (micrometers). For example, in order to manufacture one 4K display that has 4 times the resolution of a conventional high-definition screen, it is necessary to precisely array about 24.90 million chips. In order to implement improvements in the complexity and yield ratio in the processes of Micro LED chip manufacturing and the transfer process of each chip, Shin-Etsu Chemical has been working together with Shin-Etsu Group companies to take advantage of our unique materials technologies. We have proceeded to develop various advanced innovative transfer equipment and transfer parts to solve the key manufacturing challenges of Micro LED display manufacturing.

The new process technologies we are announcing were jointly developed with Dexerials Corporation (Head Office: Shimotsuke City, Tochigi Prefecture, Japan; President: Yoshihisa Shinya) and introduces innovative technology that will transfer singulated anisotropic conductive film (ACF) of Φ80μm or less onto the targeted location by laser equipment. Employing this technology, it becomes possible to transfer the singulated ACF only to the designated plate and mount the Micro LED chip on it and makes the repair process in Micro LED display manufacturing easy to carry out, a matter which had been a large issue up until now.

In addition, in order to meet the requests of customers for such matters as achieving further improvements in productivity and in the handling of a wide variety of chips, working in cooperation with two Shin-Etsu Chemical Group companies, Shin-Etsu Engineering Co, Ltd (Head Office: Tokyo; President: Kenji Sugii) and Shin-Etsu Polymer Co., Ltd. (Head Office Tokyo; President: Yoshiaki Ono), Shin-Etsu Chemical developed the following transfer equipment and transfer parts and expanded our products line-up. Combining the advantages of these Shin-Etsu transfer equipment and transfer parts, we will be able to offer the most optimized manufacturing processes to our customers:

  1. SQDP-B Series, cure type donor plate
  2. EZ-PETAMP Series, multi-stage dot-type large stamp (6 inch)
  3. Invisi LUM-X4, a 4-in-1 system that makes it possible to perform 4 processes using 1 laser
  4. BM encapsulant film for Mini LED displays
    (For details, please refer to the attached reference material.)

Shin-Etsu Chemical, as a “One-stop Solution Provider” in Micro LED manufacturing, will propose to customers’ solutions to the key challenges presented in the manufacturing processes for Micro LED displays, and we will work to spread the popularity of next-generation Micro LED displays and to expand its position in the display market.

Reference Material

1. SQDP (Shin-Etsu Quartz Donor Plate) —B Series, curing type donor plate

We developed the SQDP-B Series of curing type donor plate that makes laser lift off of Micro LED chips with a solder bump possible. By heat curing after the LED wafer is bonded, it can prevent tilting and cracking of the chips. With this curing type donor plate, laser lift off became possible for Mini LED chips on which cracks can easily have occur and for InGaN (Indium Gallium Nitride) and quaternary system red color Micro LED chips.

2. EZ-PETAMP multi-stage pattern dot-type large stamp (6 inch)

In this way, because there is no interference around the periphery of the chips, it becomes possible to greatly narrow the spacing of the extraordinarily large volume of chips that are being relocated on the second donor plate — much narrower than the pixel pitch. At the same time, by using this product, selective pick up of the chips becomes easy and a remarkable improvement in throughput as well as a reduction of the second donor plate usage volume can be realized.

3. Invisi LUM-X4, a 4-in 1 system that can handle 4 processes with one laser

Shin-Etsu Engineering will market a compact system that integrates the 4 processes that use a laser into one: multi laser lift off, laser mass transfer and high-speed trimming/repair. Unlike the existing system for mass production, not only can all laser processes, from chip singulation to mass transfer and trimming and repair, now be performed using only one laser unit, but also small-quantity production becomes feasible.

4. BM encapsulant film for Mini LED displays

With the technology which Shin-Etsu Chemical has developed of efficiently debonding the support substrate without forming tether, going forward, it is expected that Mini LED chips also will rapidly become thinner as a result of the eliminating of the sapphire support substrate.
Shin-Etsu Polymer, a Shin-Etsu Group company, has developed a film-type black matrix (BM) encapsulant film for Mini LED display applications and it is going forward with customers’ sample evaluations.
This material, in addition to improving the Mini LED display’s contrast, it also performs the function of protecting Mini LED component parts from damage or unclean substances.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For inquires about this matter, please contact:
Shin-Etsu Chemical Co., Ltd.
Public Relations Dept.
Tetsuya Koishikawa
Tel: 03-6812-2340, or from outside Japan: 81-3-6812-2340
Fax: 03-6812-2341, or from outside Japan: 81-3-6812-2341
e-mail: sec-pr@shinetsu.jp
www.shinetsu.co.jp

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SIAL Paris 2026 : The Entire Food Industry in One Place – An Unmissable Event for Professionals8.12.2025 10:00:00 EET | Press release

With less than a year to go, SIAL Parisonce again stands as a key international gathering for food industry professionals. With 85% of exhibition space already booked, the show demonstrates very strong momentum and appeal. SIAL Paris will welcome 295,000 professionals from 200 countries across a stunning 280,000 m² of exhibition space, covering all sectors of the food industry. Innovation at the core of global food transformation In a context marked by major demographic, environmental and geopolitical challenges, SIAL Paris stands as THE hub where innovation drives action, business, and transformation. It brings across all sectors’ ideas, projects, and solutions that address today’s challenges, all while inspiring food business around the world. As in every edition, the show will offer a unique immersive experience, facilitating meaningful meetings and business opportunities. SIAL Paris serves as the global international showcase for food innovation, allowing brands and companies to ex

Merz Therapeutics to Present Broad Range of Clinical, Real-World and Mechanistic Data at TOXINS 20268.12.2025 09:00:00 EET | Press release

Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that the company will present more than 20 clinical and non-clinical abstracts and posters spanning spasticity, movement disorders, and neurotoxin science at the TOXINS 2026 8th International Conference, taking place January 14–17, 2026, in Madrid, Spain. These presentations underscore the company’s commitment to addressing unmet needs in neurological disorders. “Our research reflects a relentless focus on improving patient outcomes through innovation in neurotoxin science,” said Dr. Stefan Albrecht, Chief Scientific and Medical Officer at Merz Therapeutics. “By presenting these new data at TOXINS 2026, we aim to foster scientific exchange and advance treatment strategies that address real-world challenges for patients and clinicians.” Merz Therapeutics will share new findings reflecting its continued dedication to advancing neurotoxin science. These include: Lower Limb Spasticity Incobotulinumto

Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 08:05:00 EET | Press release

Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additionally, Galderma and L’Oréal aim at exploring additional scientific research projects of mutual interest. This ongoing collaboration brings together Galderma’s scientific leadership i

Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 05:37:00 EET | Press release

Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye